Crizotinib inhibits the metabolism of tramadol by non-competitive suppressing the activities of CYP2D1 and CYP3A2
PeerJ · 2024
DOI: 10.7717/peerj.17446 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2024. Verfasst von Nanyong Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Yueqing Maternity and Child Health Hospital, Wenzhou, China. Hauptthemen laut MEDLINE: Crizotinib, Cytochrome P-450 CYP3A, Tramadol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Project of Wenzhou Municipal Science and Technology Bureau, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Objectives
To investigate the interaction between tramadol and representative tyrosine kinase inhibitors, and to study the inhibition mode of drug-interaction.
Methods
Liver microsomal catalyzing assay was developed. Sprague-Dawley rats were administrated tramadol with or without selected tyrosine kinase inhibitors. Samples were prepared and ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) was used for analysis. Besides, liver, kidney, and small intestine were collected and morphology was examined by hematoxyline-eosin (H&E) staining. Meanwhile, liver microsomes were prepared and carbon monoxide differential ultraviolet radiation (UV) spectrophotometric quantification was performed.
Results
Among the screened inhibitors, crizotinib takes the highest potency in suppressing the metabolism of tramadol in rat/human liver microsome, following non-competitive inhibitory mechanism. In vivo , when crizotinib was co-administered, the AUC value of tramadol increased compared with the control group. Besides, no obvious pathological changes were observed, including cell morphology, size, arrangement, nuclear morphology with the levels of alanine transaminase (ALT) and aspartate transaminase (AST) increased after multiple administration of crizotinib. Meanwhile, the activities of CYP2D1 and CYP3A2 as well as the total cytochrome P450 abundance were found to be decreased in rat liver of combinational group.
Conclusions
Crizotinib can inhibit the metabolism of tramadol. Therefore, this recipe should be vigilant to prevent adverse reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yueqing Maternity and Child Health Hospital, Wenzhou, China.
- Wenzhou Medical University, Wenzhou, China.
- Wannan Medical College, Wu hu, China.
- Ruian People's Hospital, Wenzhou, China.
Förderung
- Project of Wenzhou Municipal Science and Technology Bureau
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- The National Natural Science Foundation of China
- The National Key Research and Development Program of China
Zitieren
APA
Gao, N., Xu, X., Ye, F., Li, X. Y., Lin, C., Shen, X. W., & Qian, J. (2024). Crizotinib inhibits the metabolism of tramadol by non-competitive suppressing the activities of CYP2D1 and CYP3A2. PeerJ. https://doi.org/10.7717/peerj.17446
Vancouver
Gao N, Xu X, Ye F, Li XY, Lin C, Shen XW, et al. Crizotinib inhibits the metabolism of tramadol by non-competitive suppressing the activities of CYP2D1 and CYP3A2. PeerJ. 2024. doi:10.7717/peerj.17446
BibTeX
@article{Gao2024,
author = {Gao, Nanyong and Xu, Xiaoyu and Ye, Feng and Li, Xin-Yue and Lin, Chengqi and Shen, Xiu-Wei and Qian, Jianchang},
title = {Crizotinib inhibits the metabolism of tramadol by non-competitive suppressing the activities of CYP2D1 and CYP3A2},
journal = {PeerJ},
year = {2024},
doi = {10.7717/peerj.17446}
}
EUVIMED